Cargando…

Relugolix vs. Leuprolide Effects on Castration Resistance-Free Survival from the Phase 3 HERO Study in Men with Advanced Prostate Cancer

SIMPLE SUMMARY: An advanced prostate cancer research study known as HERO compared the ability of the medications relugolix and leuprolide to lower testosterone. The goal was to lower the testosterone to sustained castration levels, which is defined as below 50 ng/dL. This analysis evaluated how long...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saad, Fred, George, Daniel J., Cookson, Michael S., Saltzstein, Daniel R., Tutrone, Ronald, Bossi, Alberto, Brown, Bruce, Selby, Bryan, Lu, Sophia, Tombal, Bertrand, Shore, Neal D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571668/ https://www.ncbi.nlm.nih.gov/pubmed/37835548 http://dx.doi.org/10.3390/cancers15194854

Ejemplares similares

Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer
por: Shore, Neal D., et al.
Publicado: (2023)

Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer
por: Saad, Fred, et al.
Publicado: (2021)

Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases
por: Brown, Gordon, et al.
Publicado: (2022)

A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate Cancer
por: De La Cerda, Jose, et al.
Publicado: (2023)

Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer
por: Shore, Neal, et al.
Publicado: (2020)

A Randomized Open-Label Study of Relugolix Alone or Relugolix Combination Therapy in Premenopausal Women
por: Lukes, Andrea, et al.
Publicado: (2023)

Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors
por: Saad, Fred, et al.
Publicado: (2021)

Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)
por: George, Daniel J., et al.
Publicado: (2022)

Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation
por: Wex, Jaro, et al.
Publicado: (2013)

Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer
por: Higano, Celestia S., et al.
Publicado: (2023)

Relugolix: A Review in Advanced Prostate Cancer
por: Shirley, Matt
Publicado: (2023)

Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer
por: O’Sullivan, Joe M., et al.
Publicado: (2022)

A case of lichenoid drug eruption associated with relugolix
por: Han, Joseph, et al.
Publicado: (2023)

Correction to: Relugolix: A Review in Advanced Prostate Cancer
por: Shirley, Matt
Publicado: (2023)

Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment
por: Wallach, Joshua D., et al.
Publicado: (2021)

Relugolix – The novel oral androgen deprivation therapy for prostate cancer
por: Jena, Rahul
Publicado: (2020)

Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas
por: Al-Hendy, Ayman, et al.
Publicado: (2022)

Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia
por: Shore, Neal, et al.
Publicado: (2019)

Mini héroes
por: Jiménez Sánchez, Daniel
Publicado: (2013)

Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide
por: Shim, Myungsun, et al.
Publicado: (2019)

Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients
por: Holl, Eda K., et al.
Publicado: (2019)

Real-World Evidence Prediction of a Phase IV Oncology Trial: Comparative Degarelix vs Leuprolide Safety
por: Merola, David, et al.
Publicado: (2022)

Myocardial Infarction in a Premenopausal Woman on Leuprolide Therapy
por: Perez, Irving E., et al.
Publicado: (2015)

Bazedoxifene/conjugated estrogens in combination with leuprolide for the treatment of endometriosis
por: Hill, Amanda M., et al.
Publicado: (2018)

SUN-421 Leuprolide Injection Induced Pituitary Apoplexy
por: Jaggi, Shirin, et al.
Publicado: (2019)

Treatment patterns and characteristics of European patients with castration-resistant prostate cancer
por: Sternberg, Cora N, et al.
Publicado: (2013)

A case of adenomyosis with leiomyoma that was effectively treated with relugolix and kamishoyosan add-on therapy
por: Sasamori, Yukifumi, et al.
Publicado: (2021)

Relugolix: A new kid on the block among gonadotrophin-releasing hormone antagonists
por: Fragkoulis, Charalampos, et al.
Publicado: (2021)

Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids
por: Syed, Yahiya Y.
Publicado: (2022)

Characteristics of submucosal leiomyomas that could cause severe hemorrhage with relugolix: an observational study
por: Wada, Yoshimitsu, et al.
Publicado: (2023)

A Practical Guide to Relugolix: Early Experience With Oral Androgen Deprivation Therapy
por: Kasparian, Saro, et al.
Publicado: (2023)

Population PK and Semimechanistic PK/PD Modeling and Simulation of Relugolix Effects on Testosterone Suppression in Men with Prostate Cancer
por: Lee, Tien‐Yi, et al.
Publicado: (2022)

Hemophilia and sexual health: results from the HERO and B-HERO-S studies
por: Blamey, Greig, et al.
Publicado: (2019)

Leuprolide-Induced Hyperosmolar Hyperglycemic State in an Elderly Patient: A Case Report and Literature Review
por: Saad, Eltaib, et al.
Publicado: (2022)

Changes in adenomyosis following elagolix vs leuprolide treatment in a patient with pelvic pain and infertility: A case report
por: Barseghyan, Mariam, et al.
Publicado: (2023)

Clinical outcomes and survival surrogacy studies of prostate‐specific antigen declines following enzalutamide in men with metastatic castration‐resistant prostate cancer previously treated with docetaxel
por: Armstrong, Andrew J., et al.
Publicado: (2017)

Persistent genital arousal disorder: Successful treatment with leuprolide (antiandrogen)
por: Deka, Kamala, et al.
Publicado: (2015)

Therapeutic Effects of Leuprorelin (Leuprolide Acetate) in Sexual Offenders with Paraphilia
por: Choi, Jong Hyuk, et al.
Publicado: (2018)

Evaluation of Hypersensitivity Reactions with Leuprolide Acetate and Triptorelin Acetate in Children
por: Metbulut, Azize Pınar, et al.
Publicado: (2021)

Pseudotumor cerebri in patient on leuprolide acetate for central precocious puberty
por: Omar, Anjumanara Anver, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0353droj7qfj0euot4ge4lkvav